SCHEDULE 13D/A: Rosalind Advisors and Affiliates Maintain Significant Stake in Delcath Systems, Directors' Appointments Confirmed

Rosalind Advisors, along with its affiliated funds and principals, filed an amended Schedule 13D disclosing their continued beneficial ownership of approximately 9.9% of Delcath Systems, Inc. common shares, while also confirming the 2020 appointments of Steven Salamon and Gilad Aharon to the company's Board of Directors.

Summary

• This document is Amendment No. 13 to a Schedule 13D filing by Rosalind Advisors, Inc. and its affiliates (Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P.) and principals (Steven Salamon, Gil Aharon) regarding their beneficial ownership in DELCATH SYSTEMS, INC.
• The filing updates the beneficial ownership information as of December 23, 2024, and confirms the prior appointment of Steven Salamon and Gilad Aharon as independent directors to Delcath's Board of Directors on May 6, 2020.
• The Reporting Persons collectively beneficially own approximately 9.9% of Delcath Systems' Common Shares, based on 33,052,385 shares outstanding as of December 24, 2024.
• This ownership is subject to 'blocker' provisions: a 9.99% limit on Preferred Stock conversion and a 4.99% limit on Warrant exercise, which prevented the Reporting Persons from fully converting or exercising their securities as of the filing event date.
• Steven Salamon was elected as a Class III director with a term scheduled to expire at the 2024 Annual Meeting of Stockholders, and Dr. Aharon was elected as a Class I director with a term scheduled to expire at the 2025 Annual Meeting of Stockholders.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive, indicating continued investor interest and board representation, but also highlights limitations due to 'blocker' provisions on full conversion/exercise of securities.

Positives

• The continued significant beneficial ownership by Rosalind Advisors and its principals indicates a sustained investment interest in Delcath Systems.
• The appointment of Steven Salamon and Gilad Aharon, who are portfolio managers of the investment advisor, to the Board of Directors suggests active oversight and potential alignment of interests between a major investor and company governance.

Negatives

• The existence of 'blockers' (9.99% for Preferred Stock conversion and 4.99% for Warrant exercise) prevents the Reporting Persons from fully converting or exercising their securities, which could limit their ability to increase their stake or influence beyond the stated percentage.

Risks

• The 'blocker' provisions on Preferred Stock conversion (9.99%) and Warrant exercise (4.99%) limit the Reporting Persons' ability to fully realize their potential ownership, which could impact their investment strategy or influence.

Future Outlook

The document does not provide explicit forward-looking statements or guidance regarding the company's future financial performance or strategic direction, beyond the scheduled terms of the newly appointed directors.

Management Comments

• Rosalind Advisors, Inc. is the investment advisor to ROFI and RMF and may be deemed to be the beneficial owner of shares held by ROFI and RMF.
• Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares of Preferred Stock held, and underlying the Reported Warrants (subject to the Warrant Blockers) held by, RMF.
• Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of any such shares.

Industry Context

This filing is a standard disclosure of significant beneficial ownership and board appointments, common for investment funds taking a substantial stake in a public company. It reflects an investor's active engagement in corporate governance, a trend seen across various industries where institutional investors seek to influence company strategy.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant investor's stake and their representation on the board, which could be viewed positively as it suggests active oversight. The 'blocker' provisions might limit the investor's ability to increase their stake further, which could affect market dynamics.
• Management: The presence of directors representing a significant investor could lead to increased scrutiny or influence on strategic decisions.

Next Steps

• Steven Salamon's term as a Class III director is scheduled to expire at the 2024 Annual Meeting of Stockholders.
• Dr. Aharon's term as a Class I director is scheduled to expire at the 2025 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

DELCATH SYSTEMS, DCTH, Schedule 13D/A, Beneficial Ownership, Rosalind Advisors, Steven Salamon, Gil Aharon, Board of Directors, Corporate Governance, Investment Fund, SEC Filing, Common Shares, Preferred Stock, Warrants